Kymera Therapeutics, Inc. (KYMR) announced its business goals for 2025, along with anticipated progress on its pipeline of immunology programs.The stock rose 8% on the announcement.Shares of KYMR have surged 47.2% in a year against the industry’s decline of 16%.Image Source: Zacks Investment ResearchKYMR’s Pipeline UpdatesKymera is developing KT-621, an investigational, first-in-class, once-daily oral degrader of STAT6. The candidate has demonstrated dupilumab-like activity and very good safety data in prec ...